🇺🇸 FDA
Patent

US 8110192

Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency

granted A61KA61K2039/505A61K2039/605

Quick answer

US patent 8110192 (Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K2039/605, A61K39/12, A61K39/21